276 related articles for article (PubMed ID: 23546223)
41. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
[TBL] [Abstract][Full Text] [Related]
42. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
[TBL] [Abstract][Full Text] [Related]
43. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
44. EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
Modernelli A; Naponelli V; Giovanna Troglio M; Bonacini M; Ramazzina I; Bettuzzi S; Rizzi F
Sci Rep; 2015 Oct; 5():15270. PubMed ID: 26471237
[TBL] [Abstract][Full Text] [Related]
45. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
[TBL] [Abstract][Full Text] [Related]
46. Effect of autophagy on multiple myeloma cell viability.
Hoang B; Benavides A; Shi Y; Frost P; Lichtenstein A
Mol Cancer Ther; 2009 Jul; 8(7):1974-84. PubMed ID: 19509276
[TBL] [Abstract][Full Text] [Related]
47. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Wada N; Kawano Y; Fujiwara S; Kikukawa Y; Okuno Y; Tasaki M; Ueda M; Ando Y; Yoshinaga K; Ri M; Iida S; Nakashima T; Shiotsu Y; Mitsuya H; Hata H
Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098
[TBL] [Abstract][Full Text] [Related]
48. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
Kraus M; Malenke E; Gogel J; Müller H; Rückrich T; Overkleeft H; Ovaa H; Koscielniak E; Hartmann JT; Driessen C
Mol Cancer Ther; 2008 Jul; 7(7):1940-8. PubMed ID: 18645004
[TBL] [Abstract][Full Text] [Related]
49. The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma.
Nikesitch N; Rebeiro P; Ho LL; Pothula S; Wang XM; Khong T; Quek H; Spencer A; Lee CS; Roberts TL; Ling SCW
Cells; 2021 Dec; 10(12):. PubMed ID: 34943972
[No Abstract] [Full Text] [Related]
50. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
51. Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.
Brem GJ; Mylonas I; Brüning A
Gynecol Oncol; 2013 Feb; 128(2):383-90. PubMed ID: 23107612
[TBL] [Abstract][Full Text] [Related]
52. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
[TBL] [Abstract][Full Text] [Related]
53. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
54. Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells.
Cheng Y; Ren X; Zhang Y; Shan Y; Huber-Keener KJ; Zhang L; Kimball SR; Harvey H; Jefferson LS; Yang JM
Autophagy; 2013 Feb; 9(2):208-19. PubMed ID: 23182879
[TBL] [Abstract][Full Text] [Related]
55. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
Landowski TH; Megli CJ; Nullmeyer KD; Lynch RM; Dorr RT
Cancer Res; 2005 May; 65(9):3828-36. PubMed ID: 15867381
[TBL] [Abstract][Full Text] [Related]
56. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
Selimovic D; Porzig BB; El-Khattouti A; Badura HE; Ahmad M; Ghanjati F; Santourlidis S; Haikel Y; Hassan M
Cell Signal; 2013 Jan; 25(1):308-18. PubMed ID: 23079083
[TBL] [Abstract][Full Text] [Related]
57. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.
Fels DR; Ye J; Segan AT; Kridel SJ; Spiotto M; Olson M; Koong AC; Koumenis C
Cancer Res; 2008 Nov; 68(22):9323-30. PubMed ID: 19010906
[TBL] [Abstract][Full Text] [Related]
58. Penfluridol induces endoplasmic reticulum stress leading to autophagy in pancreatic cancer.
Ranjan A; German N; Mikelis C; Srivenugopal K; Srivastava SK
Tumour Biol; 2017 Jun; 39(6):1010428317705517. PubMed ID: 28618969
[TBL] [Abstract][Full Text] [Related]
59. ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy.
Zhang H; Pang Y; Ma C; Li J; Wang H; Shao Z
Oncol Res; 2018 Apr; 26(3):421-429. PubMed ID: 28899456
[TBL] [Abstract][Full Text] [Related]
60. Endoplasmic reticulum stress signaling is involved in mitomycin C (MMC)-induced apoptosis in human fibroblasts via PERK pathway.
Shi K; Wang D; Cao X; Ge Y
PLoS One; 2013; 8(3):e59330. PubMed ID: 23533616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
